Heterogeneous HIV-1 Reactivation Patterns of Disulfira Disulfiram+Romidepsin Treatments

Journal of Acquired Immune Deficiency Syndromes (1999)

80, 605-613

DOI: 10.1097/qai.0000000000001958

Citation Report

#	Article	IF	Citations
1	Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. Frontiers in Microbiology, 2019, 10, 3060.	1.5	114
2	HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies. Cells, 2021, 10, 475.	1.8	24
4	Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types. Viruses, 2021, 13, 1097.	1.5	3
5	Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s). Viruses, 2021, 13, 1451.	1.5	0
6	The Current Status of Latency Reversing Agents for HIV-1 Remission. Annual Review of Virology, 2021, 8, 491-514.	3.0	44
7	Biogenesis of P-TEFb in CD4+ T cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling pathways. PLoS Pathogens, 2021, 17, e1009581.	2.1	13
8	Moving Toward a Functional Cure for HIV-1. Infectious Diseases & Immunity, 2021, Publish Ahead of Print, .	0.2	1
9	Development of a NovelIn VitroPrimary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription. Journal of Virology, 2021, 95, e0022721.	1.5	10
10	Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure. Chinese Medical Journal, 2021, 134, 2776-2787.	0.9	6
11	Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages. Journal of Virology, 2022, 96, JVI0195321.	1.5	6
12	Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases. Anti-Infective Agents, 2022, 20, .	0.1	5
13	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine, 2022, 79, 103985.	2.7	10
14	Edelfosine reactivates latent HIV-1 reservoirs in myeloid cells through activation of NF-Î°B and AP1 pathway. Virology, 2022, 574, 57-64.	1.1	0
15	Controversies in the Design of Strategies for the Cure of HIV Infection. Pathogens, 2023, 12, 322.	1.2	1